Search Results - "Misyurin, A V"

Detection of the PRAME Protein on the Surface of Melanoma Cells Using a Fluorescently Labeled Monoclonal Antibody by Sapozhnikova, K. A., Misyurin, A. V., Pestov, N. B., Meleshkina, E. G., Oreshkov, S. D., Ganzhula, E. P., Mikhailova, A. S., Korshun, V. A., Misyurin, V. A., Brylev, V. A.

“…Determination of the expression level of tumor marker PRAME protein is important both for predicting the course of the disease and for monitoring the…”
Get full text

Development of a Humanized Antibody 5D3Hu against the PRAME Tumor Antigen by Larina, M. V., Finashutina, Y. P., Lyzhko, N. A., Misyurin, V. A., Novoseletsky, V. N., Dolgikh, D. A., Solopova, O. N., Moysenovich, A. M., Balabashin, D. S., Aliev, T. K., Misyurin, A. V., Kirpichnikov, M. P.

“…The PRAME antigen, which is a significant target for monoclonal antibodies, is a tumor-specific marker that is active at all stages of tumor cell…”
Get full text

Epitope Analysis of Murine and Chimeric Monoclonal Antibodies Recognizing the Cancer Testis Antigen PRAME by Misyurin, V. A., Finashutina, Yu. P., Turba, A. A., Larina, M. V., Solopova, O. N., Lyzhko, N. A., Kesaeva, L. A., Kasatkina, N. N., Aliev, T. K., Misyurin, A. V., Kirpichnikov, M. P.

“…We investigated the epitope specificity of different monoclonal antibodies recognizing the cancer testis antigen PRAME. Antibody 5D3 binds to the fragment of…”
Get full text

Monoclonal Antibodies to PRAME Protein Slow the Development of PRAME-Expressing Tumor by Solopova, O. N., Finashutina, Yu. P., Kasatkina, N. N., Lyzhko, N. A., Turba, A. A., Kesaeva, L. A., Misyurin, V. A., Misyurin, A. V., Larina, M. V., Aliev, T. K., Kirpichnikov, M. P.

“…Two monoclonal antibodies recognizing non-overlapping epitopes of the PRAME protein were injected into immunocompetent mice to study their influence on the…”
Get full text

The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data by Misyurina, A E, Kravchenko, S K, Kovrigina, A M, Magomedova, A U, Plastinina, L V, Obukhova, T N, Misyurin, A V, Misyurin, V A, Grebenuk, L A, Babaeva, F E, Baryakh, E A, Vorobiev, A I

“…Aim of the issue was to compare clinical characteristics and treatment results of patients with follicular lymphoma (FL) with translocations involving loci of…”
Get full text

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders by Kesaeva, L. A., Bulanov, A. Yu, Finashutina, Yu. P., Tikhonova, V. V., Solopova, O. N., Misyurina, E. N., Kasatkina, N. N., Lyzhko, N. A., Misyurin, V. A., Turba, A. A., Solodovnik, A. A., Soldatova, I. N., Misyurin, A. V.

“…Molecular genetic detection of CALR gene somatic mutations is required for myeloproliferative neoplasms diagnosis and treatment according to the novel WHO…”
Get full text

Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib by Misyurin, V. A., Kalenichenko, D. V., Rudakova, A. A., Finashutina, Yu. P., Lyzhko, N. A., Tikhonova, V. V., Kesaeva, L. A., Solopova, O. N., Misyurina, A. Е., Velikanov, A. N., Baryshnikovа, M. А., Misyurin, A. V.

“…Background. PRAME gene spontaneous expression is frequently observed in a cancer cell. The protein encoded by this gene increases  the viability of tumour…”
Get full text

Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3 and DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, cyclophosphamide and rituximab (FCR) by Zakharov, S. G., Golenkov, A. K., Misyurin, V. A., Kataeva, E. V., Baryshnikova, M. A., Chuksina, Yu. Yu, Mitina, T. A., Trifonova, E. V., Vysotskaya, L. L., Chernykh, Yu. B., Klinushkina, E. F., Belousov, K. A., Finashutina, Yu. P., Misyurin, A. V.

“…Background: We have previously shown that the FAS , TNFR2 , TRAIL , DR3 , DR4/5 gene expression in patients with newly diagnosed chronic lymphoblastic leukemia…”
Get full text

Gray-zone lymphoma. Examples of rare clinical manifestation by Misyurina, A E, Kravchenko, S K, Mangasarova, Ya K, Magomedova, A U, Kovrigina, A M, Shimanovskaya, L T, Fastova, E A, Misyurin, V A, Model, S V, Chebotarev, D I, Kostina, I E, Savchenko, V G

“…Mediastinal gray-zone lymphoma (MGZL, lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma) was declared as…”
Get full text

EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE by Solodovnik, A. A., Mkrtchyan, H. S., Misyurin, V. A., Tikhonova, V. V., Finashutina, Yu. P., Kasatkina, N. N., Solopova, O. N., Votyakova, O. M., Yakimovich, O. Yu, Volodina, O. M., Kichigina, M. Yu, Medvedovskaya, E. G., Antipova, A. S., Zavodnova, I. Z., Semenova, A. A., Arakelyan, G. R., Ryabukhina, Yu. E., Kolomeytsev, O. A., Shirin, A. D., Osmanov, E. A., Misyurin, A. V.

“…Objective: to study the prognostic significance of the expression of cancer-testis (CT) genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1,…”
Get full text

Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency by Misyurin, V. A., Misyurin, A. V., Misyurina, A. E., Finashutina, Yu. P., Baryshnikovа, M. A., Burova, O. S., Kravchenko, S. K.

“…In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad…”
Get full text

B-cell lymphoma, unclassifiable, intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma by Baryakh, E A, Misyurina, A E, Kovrigina, A M, Misyurin, V A, Kravchenko, S K

“…B-cell lymphoma that is unclassifiable and intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma (BL)--(UBL) is an aggressive…”
Get full text

Cancer-testis gene expression profile in human melanoma cell lines by Misyurin, V. A., Misyurin, A. V., Lukina, A. E., Krutov, A. A., Kesaeva, L. A., Soldatova, I. N., Akhlynina, T. V., Lyzhko, N. A., Burova, O. S., Morozova, L. F., Mikhaylova, I. N., Baryshnikova, M. A., Baryshnikov, A. Yu

“…A growing number of evidence indicates that cancer-testis antigens (CTA) can be used as specific targets for immune therapy of malignant melanoma. The aim of…”
Get full text

Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera by Sokolova, M A, Turkina, A G, Melikian, A L, Sudarikov, A B, Treglazova, S A, Shukhov, O A, Gemdzhian, E G, Abdullaev, A О, Kovrigina, A M, Misyurin, A V, Pliskunova, Yu V, Ivanova, V L, Moiseeva, T N

“…To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). A total of 61 patients (41…”
Get full text

Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma by E A Baryakh, A E Misyurina, A M Kovrigina, T N Obukhova, E G Gemdzhyan, V I Vorobyev, Ya K Mangasarova, Yu Yu Polyakov, A U Magomedova, G A Klyasova, V A Misyurin, G A Yatsyk, A A Shevelev, I E Kostina, A I Vorobyev, S K Kravchenko

“…Aim. To characterize a group of patients with B-cell lymphoma (BCLU) unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s…”
Get full text

Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection by Avdonkina, N.A., Danilova, A.B., Misyurin, V.A., Prosekina, E.A., Girdyuk, D.V., Emelyanova, N.V., Nekhaeva, T.L., Gafton, G.I., Baldueva, I.A.

“…The malignancy progression is an evolutionary process in which tumor clones are selected and competed for the duration of the disease. Intratumor heterogeneity…”
Get full text

Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry by Tolstykh, T. N., Misyurina, E. N., Mingalimov, M. A., Baryakh, E. A., Zhelnova, E. I., Gagloeva, D. E., Kardovskaya, S. A., Chudnova, T. S., Zotina, E. N., Ivanova, D. D., Kochneva, O. L., Yatskov, K. V., Shimanovskaya, L. T., Mar’in, D. S., Makeshova, A. B., Chernova, N. G., Dudina, G. A., Granatkin, M. A., Semina, T. A., Misyurin, A. V., Lysenko, M. A.

“…Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults in Moscow real clinical practice according to the Moscow Cancer Registry data…”
Get full text

Basic therapeutic approaches to the management of hematology/oncology patients with new coronavirus infection (COVID-19) by Misyurina, E. N., Baryakh, E. A., Frolova, N. F., Kotenko, O. N., Mutovina, Z. Yu, Andreev, S. S., Tolstykh, T. N., Yatskov, K. V., Karimova, E. A., Makeshova, A. B., Rukavitsyn, O. A., Misyurin, A. V., Polyakov, Yu. Yu, Mingalimov, M. A., Chudnova, T. S., Gagloeva, D. E., Ivanova, D. D., Koneva, A. I., Kochneva, O. L., Zotina, E. N., Grishina, E. Yu, Shimanovskaya, L. T., Yakimets, V. N., Zhelnova, E. I.

“…In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus,…”
Get full text

COMPARATIVE ANALYSIS OF MIGRATION ACTIVITY AND INVASIVE POTENTIAL OF CULTURED SOLID TUMOR CELLS by Danilova, A. B., Nekhaeva, T. L., Misyurin, V. A., Avdonkina, N. A., Emelyanova, N. V., Baldueva, I. A.

“…Understanding of the sequence of events that ensure invasiveness of malignant cells is important for prognostic purposes. The study of the cellular and…”
Get full text

Synthesis and properties of 1,2-dihydro-4(3H)-quinazolinones by Khachatryan, D. S., Belus, S. K., Misyurin, V. A., Baryshnikova, M. A., Kolotaev, A. V., Matevosyan, K. R.

“…We modified the preparative-scale method for the synthesis of 2-aryl 1,2-dihydro-4(3 H )-quinazolinone derivatives obtained in high yields by the reaction of…”
Get full text